Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Catalyst Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | $0.32 | $0.36 | $0.34 |
| Q2 2025 | 4 | $0.32 | $0.49 | $0.40 |
| Q3 2025 | 2 | $0.35 | $0.39 | $0.37 |
| Q4 2025 | 3 | $0.30 | $0.33 | $0.32 |
| Q1 2026 | 2 | $0.35 | $0.39 | $0.37 |
| Q2 2026 | 1 | $0.40 | $0.44 | $0.42 |
| Q3 2026 | 1 | $0.43 | $0.49 | $0.46 |
| Q4 2026 | 2 | $0.49 | $0.55 | $0.52 |
Catalyst Pharmaceuticals, Inc. Earnings Date And Information
Catalyst Pharmaceuticals, Inc. last posted its earnings results on Wednesday, May 7th, 2025. The company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $0.15. The company had revenue of 141.42 M for the quarter and had revenue of 491.73 M for the year. Catalyst Pharmaceuticals, Inc. has generated $1 earnings per share over the last year ($1.31 diluted earnings per share) and currently has a price-to-earnings ratio of 13.26. Catalyst Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based on prior year's report dates.
Catalyst Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/07/2025 | Q1 2025 | $0.53 | $0.47 | -0.06 | $131.49 M | $141.42 M |
| 02/26/2025 | Q4 2024 | $0.32 | $0.47 | 0.15 | $134.17 M | $141.82 M |
| 11/06/2024 | Q3 2024 | $0.49 | $0.37 | -0.12 | $123.41 M | $128.70 M |
| 08/07/2024 | Q2 2024 | $0.42 | $0.35 | -0.07 | $111.77 M | $122.71 M |
| 05/08/2024 | Q1 2024 | $0.34 | $0.20 | -0.14 | $98.78 M | $98.51 M |
| 02/28/2024 | Q4 2023 | $0.48 | $0.33 | -0.15 | $105.93 M | $110.57 M |
| 11/08/2023 | Q3 2023 | -$0.24 | -$0.29 | -0.05 | $100.37 M | $102.69 M |
| 08/09/2023 | Q2 2023 | $0.25 | $0.36 | 0.11 | $91.71 M | $99.58 M |
| 05/10/2023 | Q1 2023 | $0.32 | $0.28 | -0.04 | $81.62 M | $85.37 M |
| 04/24/2023 | Q4 2022 | N/A | $0.24 | N/A | $58.10 M | $60.76 M |
| 11/09/2022 | Q3 2022 | $0.19 | $0.22 | 0.03 | $53.69 M | $57.24 M |
| 08/09/2022 | Q2 2022 | $0.17 | $0.20 | 0.03 | $49.21 M | $53.11 M |
| 05/10/2022 | Q1 2022 | $0.14 | $0.12 | -0.02 | $42.75 M | $43.09 M |
| 04/29/2022 | Q4 2021 | N/A | $0.09 | N/A | $38.18 M | $38.31 M |
| 11/09/2021 | Q3 2021 | $0.10 | $0.10 | 0 | $34.59 M | $35.95 M |
| 08/09/2021 | Q2 2021 | $0.09 | $0.12 | 0.03 | $31.51 M | $36.37 M |
| 05/10/2021 | Q1 2021 | $0.09 | $0.07 | -0.02 | $31.68 M | $30.21 M |
| 03/15/2021 | Q4 2020 | $0.09 | $0.11 | 0.02 | $30.11 M | $31.01 M |
| 11/09/2020 | Q3 2020 | $0.09 | $0.42 | 0.33 | $31.50 M | $29.32 M |
| 08/10/2020 | Q2 2020 | $0.09 | $0.09 | 0 | $29.48 M | $29.60 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Catalyst Pharmaceuticals, Inc. Earnings: FAQ's
Catalyst Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based offlast year's report dates.
In the previous quarter, Catalyst Pharmaceuticals, Inc. (:CPRX) reported $0.68 earnings per share (EPS) to beat the analysts' consensus estimate of $0.53 by $0.15.
The conference call for Catalyst Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Catalyst Pharmaceuticals, Inc.'s latest earnings report can be read online.
Catalyst Pharmaceuticals, Inc. (:CPRX) has a recorded annual revenue of $491.73 M.
Catalyst Pharmaceuticals, Inc. (:CPRX) has a recorded net income of $163.89 M.Catalyst Pharmaceuticals, Inc. has generated $1.38 earnings per share over the last four quarters.
Catalyst Pharmaceuticals, Inc. (:CPRX) has a price-to-earnings ratio of 13.26 and price/earnings-to-growth ratio is 0.68.